GO
Loading...

Enter multiple symbols separated by commas

Biogen Inc

More

  • Biotech investors brace for updates on key drugs Friday, 17 Apr 2015 | 1:44 PM ET
    Lab technician handling test tubes

    Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.

  • Tuesday's after-hours buzz: CSX, Intel & more Tuesday, 14 Apr 2015 | 4:59 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Take a look at some of Tuesday's after-hours buzz: Intel, Biogen & more

  • Why do drugs have such weird names? Friday, 10 Apr 2015 | 7:00 AM ET
    Pharmacist dispensing pills

    It can cost $75,000 to $250,000, and the names keep getting stranger as companies balance regulator concerns with the desire to market the product.

  • 5 biotech bets: Trading a surging sector Thursday, 9 Apr 2015 | 7:36 PM ET
    Amgen

    CNBC "Fast Money" traders discussed how to trade big names in the surging but uncertain biotechnology sector.

  • Investing in brain health: Ex-NFL star Tuesday, 7 Apr 2015 | 6:32 PM ET
    Brain

    Former NFL star Jack Brewer highlights a couple of companies investing in brain-related diseases such as Alzheimer's and Parkinson's.

  • Earnings outlook grows bleak. What to buy Wednesday, 1 Apr 2015 | 12:16 PM ET
    A file photo of a FedEx truck

    The upcoming earnings season is forging a bleak outlook for investors. CNBC Pro highlights some of the top picks on the street.

  • Cramer: The best places for you to put new money Monday, 30 Mar 2015 | 6:55 PM ET
    A Cofor worker wearing a safety hard hat moves drilling pipes near to a rig at the geothermal energy drilling site operated by Semhach SA in Villejuif, France.

    Jim Cramer reveals the top places to invest new money on the stock market.

  • Cramer: 4 horsemen of biotech & semis are back Sunday, 29 Mar 2015 | 1:33 PM ET
    A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange, July 18, 2014.

    Jim Cramer saw the proximate cause of this week's decline to these stocks. Now they're showing signs of life.

  • Biotech woes: Deja vu all over again Thursday, 26 Mar 2015 | 12:59 PM ET
    Biotech

    For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.

  • Drugs companies unite to mine genetic data Thursday, 26 Mar 2015 | 2:25 AM ET

    Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.

  • *Eisai drops on after soaring 32 pct over the last 2 days. TOKYO, March 25- Japan's Nikkei share average edged down on Wednesday morning in choppy trade as U.S. shares languished, but losses were limited by investor appetite for stocks before they go ex-dividend later this week. Outperforming the market was Santen Pharmaceutical Co, which jumped as high as 9.2...

  • Stocks close lower; weaker dollar eyed Monday, 23 Mar 2015 | 4:01 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed lower as investors looked ahead to a light week of economic reports amid some consolidation in currency and oil prices.

  • Call of the Day: Downgrading Biogen   Monday, 23 Mar 2015 | 12:52 PM ET
    Call of the Day: Downgrading Biogen

    Biogen Idec will simply be known as Biogen, and the stock is lower after a downgrade by Stifel Nicolaus to hold.

  • Wall Street uneasy ahead of busy data week Monday, 23 Mar 2015 | 8:25 AM ET
    A trader works on the floor of the New York Stock Exchange.

    U.S. stock index futures indicated a lower open on Monday, amid some dollar and oil price weakness, ahead of a busy week of data releases.

  • Early movers: Biogen, Staples, Pfizer & more Monday, 23 Mar 2015 | 8:16 AM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Monday's early movers:

  • Biogen takes aim at Alzheimer's, ALS drugs Monday, 23 Mar 2015 | 6:48 AM ET
    A multiple sclerosis drug manufactured at the Biogen Idec manufacturing plant in Cambridge, Mass.

    Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.

  • Cramer Remix: Cha-ching! Time to cash in Friday, 20 Mar 2015 | 7:26 PM ET
    Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer on why this rally won’t last forever and why you should take some off the table on this.

  • 6 trades on surging biotech sector Friday, 20 Mar 2015 | 6:39 PM ET

    Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.

  • *Nike rises after results, outlook. March 20- U.S. stocks rose on Friday, pushing the Nasdaq to a 15- year high and helping the S&P 500 snap a three-week string of losses, following a pullback in the dollar, upbeat results from Nike and further biotech gains. Among early reporters, Nike jumped 3.7 percent to $101.98 as the biggest boost to the Dow after it posted a...

  • *Nike rises after results, outlook. March 20- U.S. stocks rose on Friday, pushing the Nasdaq to a 15- year high and helping the S&P 500 snap a three-week string of losses, following a pullback in the dollar, upbeat results from Nike and further biotech gains. Among early reporters, Nike jumped 3.7 percent to $101.98 as the biggest boost to the Dow after it posted a...